Paul Chung, MD
Urology · Philadelphia, PANPI 1063702702
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (53.1%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. Boston Scientific accounts for 61.4% of it on its own, with 17 other manufacturers making up the rest. Reporting peaked in 2024 at $36,152 and has fallen 52.6% since, to $17,152 in 2025. Among urology clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 285 payments — averaging $422.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$74K
- Coloplast$36K
- Merck$9K
- Medtronic$279
- Astellas Pharma US Inc$153
- Photocure Inc$123
- plus $571 from 12 others
Across 19 payments — averaging $14,190 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Coloplast$152K
- Boston Scientific$87K
- Medtronic$30K
- Bracco Diagnostics Inc.$574
What the payments were for
- Consulting fees$63,88253%
- Speaking & faculty fees$44,39437%
- Travel & lodging$5,2854%
- Food & beverage$6,8046%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 179 | $73,855 |
| Coloplast | 54 | $36,003 |
| Merck | 12 | $9,380 |
| Medtronic | 2 | $279 |
| Astellas Pharma US Inc | 10 | $153 |
| Photocure Inc | 3 | $123 |
| Neotract Inc. | 5 | $121 |
| Johnson & Johnson | 5 | $102 |
| Sumitomo Pharma America, Inc. | 4 | $89 |
| Smith+Nephew | 2 | $59 |
| Urogen Pharma, Inc. | 2 | $54 |
| Rigicon,inc. | 1 | $33 |
| Progenics Pharmaceuticals, Inc. | 1 | $29 |
| Telix Pharmaceuticals | 1 | $23 |
| Tolmar Pharmaceuticals, Inc. | 1 | $20 |
| Idorsia Pharmaceuticals US Inc | 1 | $16 |
| Avation Medical, Inc. | 1 | $14 |
| Endo Pharmaceuticals Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TITAN$19,938
- AMS 700 CXR RTE KIT$15,800
- AMS 800 Artificial Urinary Sphincter$11,537
- GENERAL - THERAPIES$8,925
- SPEEDICATH$7,796
- GENERAL ERECTILE DYSFUNCTION$7,530
- AMS$6,681
- OPTIFLEX$6,400
- Luja Coude$6,048
- UROMAX ULTRA$4,000
- ADVANCE$1,000
- AMS 700$785
- Porges Coloplast$480
- INTERSTIM$279
How this compares
$120,364 in reported general payments places this provider in the 95th percentile of 596 urology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 53 | $56,162 |
| GemtesaVibegron | 26 | $29,614 |
| Tamsulosin Hcl | 201 | $4,615 |
| Testosterone | 11 | $3,759 |
| Tadalafil | 18 | $3,200 |
| Oxybutynin Chloride ErOxybutynin Chloride | 69 | $2,519 |
| Solifenacin Succinate | 18 | $1,609 |
| Finasteride | 98 | $1,420 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 35 | $1,305 |
| Testosterone Cypionate | 30 | $567 |
| Oxybutynin Chloride | 12 | $64 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $153 | $56,16253 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $89 | $29,61426 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 596 urology providers in Pennsylvania.
Other urology in Philadelphia
- Demetrius BagleyPhiladelphia$739K
- Daniel EunPhiladelphia$226K
- Leonard GomellaPhiladelphia$190K
- Phillip GinsbergPhiladelphia$145K
- Edouard TrabulsiPhiladelphia$137K
- Siobhan HartiganPhiladelphia$121K
- William JaffePhiladelphia$119K
- Robert UzzoPhiladelphia$111K
- Jay SimhanPhiladelphia$110K
- Trinity BivalacquaPhiladelphia$100K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.